<DOC>
	<DOCNO>NCT02424669</DOCNO>
	<brief_summary>Amyotrophic Lateral Sclerosis ( ALS ) common motor neuron disease . It consider rare disease prevalence 8 per 100,000 person . Initiating mid-life progressive paralysis , evolve rapidly generalized muscle waste lead irrevocably death within 2 5 year clinical onset . Since cure ALS , management disease supportive palliative . Riluzole drug show extend survival three month . The identification biomarkers sensitive progression disease might enhance diagnostic provide new drug target . Dysfunction immune system pathological hallmark ALS . Increased level interferon gamma ( IFNgamma ) find serum cerebrospinal fluid ( CSF ) ALS patient . However , cell origin well pathogenic influence peripheral source IFNg unknown . Thus , IFNgamma might role pathogenic process ALS might potential biomarker disease .</brief_summary>
	<brief_title>Neuroinflammation Amyotrophic Lateral Sclerosis - Mechanisms Therapeutic Perspectives : Translational Pilot Study Among ALS Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Group 1 Group 2 : sporadic ALS ( without family history ) , recently diagnose ( onset first symptoms &lt; 24 month ) group 1 , recently diagnose ( onset first symptoms &gt; 24 month ) group 2 Who meet laboratorysupported probable , probable definite form ALS accord El Escorial criterion Suffering spinal form ALS Group 3 : inflammatory peripheral neuropathy , non inflammatory peripheral neuropathy , recently diagnose Familial form ALS Bulbar form respiratory onset form ALS Subjects clinically significant history unstable severe cardiac , oncologic , hepatic renal disease , medically significant illness . Subjects significant cognitive impairment , clinical dementia , psychiatric illness . Female childbearing potential ( apart patient use adequate contraceptive measure ) , pregnant breast feeding Suspected inability complete study followup ( foreign worker , transient visitor , tourist others followup evaluation assure ) Participation clinical study within 30 day prior Screening Visit Persons deprive freedom judicial administrative decision , hospitalize without consent reason research , legal protection unable express consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>